Built to make the U.S. biosimilars market easier to follow.
All Things Biosimilar (ATB) is a market intelligence and reporting platform designed for teams that need clarity fast — without rebuilding the story from scratch every week.
Mission
ATB exists to help organizations monitor the U.S. biosimilars market with confidence. We turn complexity into consistent, referenceable insight so teams can stay aligned and make better decisions faster.
What ATB delivers
Timely insights
Week-to-week market changes captured on a consistent cadence.
Unparalleled experience
Underpinned by 15+ years focused exclusively on U.S. biosimilars.
Robust analysis
Synthesis across news, primary sources, datasets, and intelligent tools.
Strategy + systems + execution.
ATB is designed and built by Bourgoin Insights Group (BIG). BIG partners with organizations to define strategy and build the systems that support it — with a focus on efficiency, clarity, and real execution, supported by modern technology and intelligent tools.
Grounded in experience
ATB is underpinned by deep, exclusive experience in the U.S. biosimilars market. That experience influences what we prioritize, how we frame developments, and the context we bring to each report.
Ready to explore the reports?
Start with the 351(k) Report, or log in if you already have access.